(Q43202107)

16 November 2017

title

Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial (English)

1 reference

16 November 2017

1 reference

Subhrojyoti Bhowmick

1

1 reference

16 November 2017

Avijit Hazra

series ordinal

2

1 reference

16 November 2017

Malati Ghosh

series ordinal

3

1 reference

16 November 2017

language of work or name

1 reference

1 March 2010

1 reference

Australian and New Zealand Journal of Psychiatry

16 November 2017

published in

1 reference

16 November 2017

volume

44

1 reference

16 November 2017

issue

3

1 reference

16 November 2017

page(s)

237-242

1 reference

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

16 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00048670903487134

The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048670903487134

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048670903487134

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048670903487134

The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048670903487134

Safety of amisulpride (Solian): a review of 11 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048670903487134

10.3109/00048670903487134

21 January 2018

Identifiers

DOI

1 reference

16 November 2017

1 reference